DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
DBV Technologies, a clinical-stage biopharmaceutical company, will report its full year 2022 financial results and provide a business update on March 2, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DBV Technologies, a clinical-stage biopharmaceutical company, will report its full year 2022 financial results and provide a business update on March 2, 2023. The company will host a conference call and live audio webcast at 5:00 p.m. ET, where participants can dial in using US: 1-866-777-2509 or International: 1-412-317-5413. The event will also be streamed on the company’s website, with a replay available afterward. DBV Technologies specializes in epicutaneous immunotherapy through its proprietary platform, Viaskin, aimed at transforming food allergy care.
Details
News Market Reaction – DBVT
The recorded move for DBVT in the trading session of this news was +2.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Montrouge, France, February 27, 2023
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, March 2, at 5:00 p.m. ET to report full year 2022 financial results and provide a business update.
Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call:
- United States: 1-866-777-2509
- International: 1-412-317-5413
A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV Technologies.
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.